# Aspira Women’s Health Inc. (AWHL) · Edgar & Edgarette company card

> Aspira Women’s Health Inc. (AWHL) grew revenue 0.4% in FY2025 to $9 million, operating margin -85.9% against a -4.3% median for in vitro & in vivo diagnostic substances, equity -127% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 926617 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/AWHL) · [JSON](https://www.pops4.com/boards/company/AWHL.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $9M |
| Revenue growth, 1 year | 0.4% |
| Revenue growth per year | 7.8% |
| Operating margin | -85.9% (prior year -177.3%) |
| Net margin | -138.7% |
| Operating cash flow | −$7M |
| Capital spending | $16,000 |
| Free cash flow | −$7M |
| Cash | $2M |
| Long-term debt | $1M |
| Total assets | $5M |
| Total equity | −$7M |
| Equity ÷ assets | -127.1% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -334.76 (distress zone)
- Piotroski F: 6 of 9 (solid)
- Beneish M: -7.05 (below the −1.78 line)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed late annual report notice, earlier statements no longer to be relied on in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative; operating loss: a margin of -85.9% in FY2025; revenue is hard to predict: its 80% range is ±45%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $9.2M (FY2025), total debt $1.3M. Experience: revenue up 0.4% on the year, up 7.8% a year over 4 years; operating margin -85.9%, up from -177.3%. Soundness: equity -127.1% of assets (liabilities exceed assets). Credibility: four or more audited years, moderate weight, marked down from reasonable: on 2026-11-16 the company said earlier statements should no longer be relied on (8-K Item 4.02), and no 10-K has been filed since. Range: 80% of past cases like this landed between $5.7M and $14.9M next year (method v4.1: its own 4-year record of growth weighed at 50% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $5.3M to $16.0M. A statistical range, not company guidance. Against peers (161 filers, $50M+ revenue, its industry group): operating margin -85.9% against a -4.3% median; growth 0.4% against 12.6%.

Range logged 2026-11-17, receipt fedfde91f1c1ecad, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item NT 10-K Late annual report notice: 1, latest 2026-04-01 ([filing](https://www.sec.gov/Archives/edgar/data/926617/000092661726000016/0000926617-26-000016-index.htm))
- Item 4.02 Earlier statements no longer to be relied on: 1, latest 2026-11-16 ([filing](https://www.sec.gov/Archives/edgar/data/926617/000092661726000058/0000926617-26-000058-index.htm))
- Item 5.02 Director or officer change: 2, latest 2026-06-22 ([filing](https://www.sec.gov/Archives/edgar/data/926617/000092661726000047/0000926617-26-000047-index.htm))

## Recent filings

- 10-Q · filed 2026-11-16 · [filing](https://www.sec.gov/Archives/edgar/data/926617/000092661726000060/0000926617-26-000060-index.htm)
- 8-K · filed 2026-11-16 · 4.02 Non-Reliance on Previously Issued Financial Statements · [filing](https://www.sec.gov/Archives/edgar/data/926617/000092661726000058/0000926617-26-000058-index.htm)
- 10-Q · filed 2026-08-14 · [filing](https://www.sec.gov/Archives/edgar/data/926617/000092661726000054/0000926617-26-000054-index.htm)
- 8-K · filed 2026-07-15 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/926617/000092661726000052/0000926617-26-000052-index.htm)
- 8-K · filed 2026-06-22 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/926617/000092661726000047/0000926617-26-000047-index.htm)
- 8-K · filed 2026-06-17 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/926617/000092661726000045/0000926617-26-000045-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000926617.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=926617

## Cite

POPS4, Edgar & Edgarette: Aspira Women’s Health Inc. (AWHL) company card, from the company's own SEC filings, accessed 2026-11-17, https://www.pops4.com/boards/company/AWHL. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

